Journal article
Potential Clinical Utility of a Targeted Circulating Tumor DNA Assay in Esophageal Adenocarcinoma
CS Cabalag, M Yates, MB Corrales, P Yeh, SQ Wong, BZ Zhang, KM Fujihara, L Chong, MW Hii, SJ Dawson, WA Phillips, CP Duong, NJ Clemons
Annals of Surgery | Published : 2022
Abstract
Objective: To explore the clinical utility of circulating tumor DNA (ctDNA) in esophageal adenocarcinoma (EAC) by developing a cost-effective and rapid technique utilising targeted amplicon sequencing. Summary of background data: Emerging evidence suggests that levels of ctDNA in the blood can be used to monitor treatment response and in the detection of disease recurrence in various cancer types. Current staging modalities for EAC such as computerised tomography of the chest/abdomen/pelvis (CT) and positron emission tomography (PET) do not reliably detect occult micro-metastatic disease, the presence of which signifies a poor prognosis. After curative-intent treatment, some patients are sti..
View full abstractGrants
Awarded by Cancer Council Victoria
Awarded by Department of Health and Human Services acting through the Victorian Cancer Agency, Victoria, Australia
Awarded by NHMRC/MRFF investigator grant
Funding Acknowledgements
This research was supported by a Grant-In-Aid (APP 1156945 to NJC, WAP, CPD and SJD) from the Cancer Council Victoria a research grant from the AVANT foundation, and a Translational Research Project grant (TRP15012 to WAP, NJC and CPD) from the Department of Health and Human Services acting through the Victorian Cancer Agency, Victoria, Australia. CSC is the recipient of, and supported by, The Alan & Kate Gibson Research Fellowship, 2018. NJC is supported by a Fellowship (MCRF16002) from the Department of Health and Human Services acting through the Victorian Cancer Agency, Victoria, Australia. PY is supported by grant funding administered by the Snowdome Foundation, Maddie Riewoldt's Vision and an NHMRC/MRFF investigator grant (#1195030). Data sharing statement: Forward and reverse primer sequences for amplicon design, individual participant clinico-pathological data, baseline variant calling, follow-up variant calling, and outcomes are provided in the supplementary tables, http://links.lww.com/SLA/D402.For raw sequencing data of individual patients, please submit a request to the corresponding author, Associate Professor Nicholas J Clemons.